SPECIAL NOTE: We’ve just released next quarter’s Ultimate Four report, which includes four stocks our team believes have the greatest upside potential over the upcoming quarter. This latest report features favorite stocks from Sheraz Mian, Brian Hamilton, Brian Bolan and David Borun. Log on to Zacks.com to see these stocks today. The market came pretty close to giving back all of the morning’s solid gains on Friday, but the major indices endured the late session selloff and closed in positive territory. Unfortunately, the week was a different story. The Dow jumped nearly 300 points at its best today but would give most of that back by the closing bell. It finished with an advance of 0.23% (or about 55 points) to 24,271.4. The NASDAQ climbed 0.09% to 7510.3, while the S&P was up 0.08% to 2718.4. These indices also came sharply off their highs. The Russell 2000 couldn’t even stay in the green, sliding 0.12% to 1643.1. The indices missed a chance to take a big bite out of their weekly losses. The NASDAQ and Russell were holding up the best during all this trade turmoil, but they really got hit this week and led the way lower with losses of approximately 2.4% and 2%, respectively. They were impacted by news of President Trump setting up investment restrictions on foreign companies, though the administration softened its stance later in the week. The S&P and Dow each slipped by about 1.3% over the last 5 days. Today also marked the end of the month and the first half…and you can really see how the Dow has been under pressure since January due to fears of rising rates and a potential trade war. It is the only one of the Big 3 that’s down for June (-0.6%) and the year to date (-1.8%). The NASDAQ was the best performer in that time as the trade concerns have only recently taken a toll. It was up nearly 1% this month and has gained about 8.8% in 2018. The S&P was up 0.4% in June and 1.7% in the first 6 months. The first half has certainly been volatile. It started optimistically enough with all-time highs coming off a spectacular 2017. But the first challenge came from fears of rising rates. Then the White House started imposing tariffs that are scheduled to take effect next week. Also in the mix, though, was a solid earnings season. What will the second half bring? Despite all the challenges, the editors are still encouraged by the economy and the market. They are already preparing to capitalize on opportunities in the back half. Friday was busy in the portfolios for what was expected to be a sleepy summer session. Let’s get right to the action: Today's Portfolio Highlights: Healthcare Innovators: Kevin took gains of nearly 120% on Sarepta Therapeutics (SRPT) in March and was looking for a re-entry this spring. But then the stock “got away” in June after it surged on promising early results for a gene therapy program to fight Duchenne muscular dystrophy (DMD). Not only did its share price take off above $160, but so too did the ratings and price targets of Wall Street biotech analysts. So the stock’s recent pullback to below $135 gives the editor another solid opportunity to get in before the next run higher. And he’d be willing to buy even more if it continues to slip, especially since the consensus target is now above $185. Make sure to read the complete commentary. Home Run Investor: The chip sector doesn’t seem to have the same legs as before, so Brian Bolan thought this was a good time to cash in Immersion Corp. (IMMR). The company develops technologies that allow users to interact with computers using touch…and it was added back on March 1. It has done well during that time and leaves the portfolio today with a 34.2% return. Large-Cap Trader: The portfolio ended the week by adding three GARP (Growth at a Reasonable Price) stocks. Each one of the names have Zacks Style Scores of “A” for Value AND Growth, as well as high Zacks Industry Rank positions. The new buys are: • Tokyo Electron (TOELY): a Japanese electronic products company for industrial uses that should help the portfolio “thread the needle” during the China-U.S. trade turmoil. It reports again on July 26. • Centene Corporation (CNC): a top notch healthcare services stock that reports on July 24th. • UnitedHealth Group (UNH): another solid healthcare services stock on a momentum run, but this one doesn’t report until mid August. John is investing in these names equally. Read the complete commentary for the editor’s detailed analysis of each new pick. Counterstrike: In its first report as a publicly-traded company, DocuSign (DOCU) announced a positive surprise of 117% that sent shares sharply higher. But since that early June report, shares of this Zacks Rank #2 (Buy) provider of e-signature solutions have slipped back into the low $50s as the market struggled. Jeremy believes the company has a lot of upside potential for the long-term, which means the recent pullback is a buying opportunity. He added DOCU on Friday with a 12% allocation and is expecting the stock to make it to the $70 area. Read the full write-up for more. Technology Innovators: Although the chip space has been getting hit pretty hard recently, Brian Bolan saw an opportunity to pick up Cohu (COHU) “on the cheap”. This Zacks Rank #2 (Buy) is a semiconductor test company and has shown consistent revenue growth, which the editor always loves to see. He thinks this stock can recover 5% to 10% in the near term if the broader market holds up. Read the complete commentary for more. Momentum Trader: Shares of Liberty Media Formula One Group (FWONA) have been in high gear since its most recent quarterly report. This company is the parent of the Formula One Group, which promotes the international FIA Formula One Racing Championship. As part of the Media Conglomerates space, it is in the top 7% of the Zacks Industry Rank. And now the company has worked out a deal with Amazon Web Services that will unlock a ton of archived data for fans that stretches back decades. Dave says this stock is “burning rubber down the track”, so he added it to the portfolio on Friday. Read the full write up for more. Have a Great Weekend! Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >> Zacks Investment Research